Peptide · Agonist of parathyroid hormone 1 receptor (PTH1R) · developed by Ascendis Pharma Bone
Palopegteriparatide is a prodrug that releases PTH(1-34), a parathyroid hormone analog, to maintain continuous systemic exposure. The released peptide acts on the parathyroid hormone 1 receptor, highly expressed on osteoblasts, osteocytes and renal tubular cells, to raise serum calcium and lower serum phosphate. It is studied in hypoparathyroidism.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 12, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07345494 | N/A | Hypoparathyroidism | Recruiting | ASND |
| NCT05654701 | N/A | Hypoparathyroidism | Approved for marketing | ASND |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hypoparathyroidism
Updated Oct 11, 2026. Something wrong or missing? Report it on the ASND page.
See ASND's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ASND catalysts and pipeline →